Inbiogen Overview

  • Year Founded
  • 2008

Year Founded

  • Status
  • Public

  • Employees
  • 29

Employees

  • Stock Symbol
  • 101140

Stock Symbol

  • Investments
  • 3

  • Share Price
  • $3.53
  • (As of Tuesday Closing)

Inbiogen General Information

Description

Inbiogen is engaged in kiosk distribution and F&B business. The kiosk industry, which features payment functionality and the F&B business is engaged in restaurant.

Contact Information

Formerly Known As
ARTIS, BtOne
Ownership Status
Publicly Held
Financing Status
Corporate Backed or Acquired
Corporate Office
  • 2nd floor, 21, Eonju-ro 135-gil
  • Gangnam-gu
  • Seoul
  • South Korea
Primary Industry
Computers, Parts and Peripherals
Other Industries
Business/Productivity Software
Biotechnology
Holding Companies
Stock Exchange
KRX
Vertical(s)
Corporate Office
  • 2nd floor, 21, Eonju-ro 135-gil
  • Gangnam-gu
  • Seoul
  • South Korea

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Inbiogen Stock Performance

As of 17-Nov-2026, Inbiogen’s stock price is $3.53. Its current market cap is $35.2M with 10M shares.

(As of Tuesday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$3.53 $3.54 $3.13 - $9.43 $35.2M 10M 3.78K -$1.43

Inbiogen Financials Summary

As of 30-Jun-2026, Inbiogen has a trailing 12-month revenue of $3.52M.

In Thousands,
USD
TTM 30-Jun-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 38,358 72,650
Revenue 3,517 4,425 5,160 4,773
EBITDA (14,739) (1,294) 11,951 9,221
Net Income (14,282) (997) 11,816 8,677
Total Assets 95,190 111,106 110,477 113,064
Total Debt 2,624 811 607 460
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Inbiogen Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Inbiogen‘s full profile, request access.

Request a free trial

Inbiogen Patents

Inbiogen Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
JP-2025066744-A Information processing device, information processing method, and program Pending 31-Aug-2023
JP-2024159600-A Course guide support system, course guide support method, and program Active 28-Apr-2023
JP-2024070855-A Information processing device, information processing system, and information processing method Active 11-Nov-2022
JP-2022162668-A Personnel management system, server, personnel management method, and program Active 13-Apr-2021
JP-6674988-B2 Simulation apparatus, simulation system, program, and simulation method Active 21-Sep-2018
To view Inbiogen’s complete patent history, request access »

Inbiogen Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Inbiogen Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Inbiogen‘s full profile, request access.

Request a free trial

Inbiogen Investments (3)

Inbiogen’s most recent deal was a PIPE with Vidente for . The deal was made on 28-Apr-2022.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Vidente 28-Apr-2022 PIPE Electronics (B2C)
Vidente 30-Dec-2021 PIPE Electronics (B2C)
HaimBio 20-Nov-2020 Corporate Biotechnology
To view Inbiogen’s complete investments history, request access »

Inbiogen ESG

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

Rank

Percentile

Technology Hardware

Industry

Rank

Percentile

Electronics Equipment

Subindustry

Rank

Percentile

To view Inbiogen’s complete esg history, request access »

Inbiogen Exits (1)

Inbiogen’s most recent exit was on 20-Nov-2020 from HaimBio. The exit was categorized as .

Company Name Exit Date Exit Type Exit Size Status Buyers
HaimBio 20-Nov-2020 Completed
To view Inbiogen’s complete exits history, request access »

Inbiogen FAQs

  • When was Inbiogen founded?

    Inbiogen was founded in 2008.

  • Where is Inbiogen headquartered?

    Inbiogen is headquartered in Seoul, South Korea.

  • What is the size of Inbiogen?

    Inbiogen has 29 total employees.

  • What industry is Inbiogen in?

    Inbiogen’s primary industry is Computers, Parts and Peripherals.

  • Is Inbiogen a private or public company?

    Inbiogen is a Public company.

  • What is Inbiogen’s stock symbol?

    The ticker symbol for Inbiogen is 101140.

  • What is the current stock price of Inbiogen?

    As of 17-Nov-2026 the stock price of Inbiogen is $3.53.

  • What is the current market cap of Inbiogen?

    The current market capitalization of Inbiogen is $35.2M.

  • What is Inbiogen’s current revenue?

    The trailing twelve month revenue for Inbiogen is $3.52M.

  • What is Inbiogen’s annual earnings per share (EPS)?

    Inbiogen’s EPS for 12 months was -$1.43.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process